Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index; 7 of the 16 sources its claims cite were checked for support.

Epidermal hepcidin is required for neutrophil response to bacterial infection

Open access

Abstract

Novel approaches for adjunctive therapy are urgently needed for complicated infections and patients with compromised immunity. Necrotizing fasciitis (NF) is a destructive skin and soft tissue infection. Despite treatment with systemic antibiotics and radical debridement of necrotic tissue, lethality remains high. The key iron regulatory hormone hepcidin was originally identified as a cationic antimicrobial peptide (AMP), but its putative expression and role in the skin, a major site of AMP production, have never been investigated. We report here that hepcidin production is induced in the skin of patients with group A Streptococcus (GAS) NF. In a GAS-induced NF model, mice lacking hepcidin in keratinocytes failed to restrict systemic spread of infection from an initial tissue focus. Unexpectedly, this effect was due to its ability to promote production of the CXCL1 chemokine by keratinocytes, resulting in neutrophil recruitment. Unlike CXCL1, hepcidin is resistant to degradation by major GAS proteases and could therefore serve as a reservoir to maintain steady-state levels of CXCL1 in infected tissue. Finally, injection of synthetic hepcidin at the site of infection can limit or completely prevent systemic spread of GAS infection, suggesting that hepcidin agonists could have a therapeutic role in NF.

Overview

CoChat Summary

TL;DR

Epidermal keratinocyte-derived hepcidin is induced during group A Streptococcus necrotizing fasciitis and limits bacterial spread by promoting CXCL1-dependent neutrophil recruitment. Local synthetic hepcidin treatment prevented systemic dissemination in a mouse NF model, suggesting a potential adjunctive therapeutic strategy.

Key findings

  • In a GAS necrotizing fasciitis mouse model, keratinocyte-specific hepcidin deficiency (Hamp1Δker) increased bacterial burden 4 days after infection at the lesion site (10^6 vs 10^5 CFU/mg), in blood (10^4 vs 9 × 10^2 CFU/mL), and in spleen (5 × 10^4 vs 38 CFU/g) compared with Hamp1lox/lox littermates.
  • Hepcidin had no direct bactericidal or bacteriostatic activity against GAS, but induced a dose-dependent increase in CXCL1 in primary keratinocytes at 0.36 μM and 3.6 μM; Hamp1Δker mice showed lower keratinocyte CXCL1 and less neutrophil recruitment in infected skin.
  • CXCL1 was cleaved by GAS SpyCEP into 2 fragments of 5.9 kDa and 1.3 kDa, whereas hepcidin was not cleaved by SpyCEP or SpeB, suggesting hepcidin can act as a protease-resistant reservoir for maintaining CXCL1.
  • In the NF model, local injection of 1 μg synthetic hepcidin at 24 hours after infection followed by 500 ng on 2 consecutive days resulted in 7 of 9 hepcidin-treated mice showing no bacterial dissemination, whereas all control mice had systemic dissemination; the effect was absent in CXCL1–/– mice.

Methods

  • Human skin biopsies from patients with GAS NF were compared with healthy skin, and hepcidin induction was tested in a human 3D organotypic skin model after GAS infection.
  • Mice with keratinocyte-specific hepcidin deficiency (Hamp1Δker) were generated by crossing Hamp1lox/lox with K14cre+ mice and infected subcutaneously with a patient-derived GAS NF strain; outcomes included CFU in lesion, blood, and spleen, weight loss, histology, ELISA, and cytometry.
  • In vitro assays used primary murine keratinocytes, HaCaT cells, synthetic hepcidin, CXCL1/IL-8 measurement, iron/FPN antagonist treatment, and mass spectrometry after incubation with purified SpyCEP or SpeB; detailed methods are stated to be in Supplemental Methods.

Limitations

  • The paper states that future studies should investigate whether skin hepcidin levels inversely correlate with severity of sepsis development in patients with NF.
  • The main text repeatedly refers to Supplemental Methods and supplemental figures/tables, so detailed experimental and statistical methods are not available in the provided text (evident).
  • The therapeutic evidence comes from a mouse NF model and in vitro systems; human data are limited to skin biopsies and a 3D skin model, with no human treatment trial reported (evident).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1172/jci126645

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Keratinocyte hepcidin prevents bacterial systemic spread. IHC with or without primary antibody detecting (A) hepcidin (in brown) on sections of cutaneous human biopsies of GAS NF patients and healthy control using PerkinElmer’s Lamina multilabel slide scanner Panoramic Viewer software. (B) Real-time reverse transcription PCR (qPCR) for hepcidin from GAS-infected human 3D organotypic skin equivalent model; n = 4 per group. (C) qPCR for hepcidin in murine GAS-infected skin; n ≥ 3 per group. (D) Hepcidin (in blue) and K14 (in brown) IHC on cutaneous biopsies of WT mice challenged or not with GAS. Scale bars: 100 μm. Leica DMI3000B microscope, Leica DFC310FX camera, 5/0.4; Leica LAS Core software. (E) Generation of Hamp1Δker mice. (F) Plasma iron, ferritin, transferrin, and skin iron levels in Hamp1lox/lox and Hamp1Δker mice; n ≥ 4 per group. (G) Bacterial count in skin, blood, and spleen of Hamp1lox/lox and Hamp1Δker mice 4 days after injection with GAS; n ≥ 10 per group. (H) Weight variation of Hamp1lox/lox and Hamp1Δker mice during infection; n = 10 per group. Statistical analysis was performed using a Mann Whitney test (B, C, F, and G) or a 2-way ANOVA followed by Tukey’s test for weight kinetics (H). *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 1 Keratinocyte hepcidin prevents bacterial systemic spread. IHC with or without primary antibody detecting (A) hepcidin (in brown) on sections of cutaneous human biopsies of GAS NF patients and healthy control using PerkinElmer’s Lamina multilabel slide scanner Panoramic Viewer software. (B) Real-time reverse transcription PCR (qPCR) for hepcidin from GAS-infected human 3D organotypic skin equivalent model; n = 4 per group. (C) qPCR for hepcidin in murine GAS-infected skin; n ≥ 3 per group. (D) Hepcidin (in blue) and K14 (in brown) IHC on cutaneous biopsies of WT mice challenged or not with GAS. Scale bars: 100 μm. Leica DMI3000B microscope, Leica DFC310FX camera, 5/0.4; Leica LAS Core software. (E) Generation of Hamp1Δker mice. (F) Plasma iron, ferritin, transferrin, and skin iron levels in Hamp1lox/lox and Hamp1Δker mice; n ≥ 4 per group. (G) Bacterial count in skin, blood, and spleen of Hamp1lox/lox and Hamp1Δker mice 4 days after injection with GAS; n ≥ 10 per group. (H) Weight variation of Hamp1lox/lox and Hamp1Δker mice during infection; n = 10 per group. Statistical analysis was performed using a Mann Whitney test (B, C, F, and G) or a 2-way ANOVA followed by Tukey’s test for weight kinetics (H). *P < 0.05; **P < 0.01; ***P < 0.001.CC BY · PubMed Central
Figure 2 Hepcidin promotes CXCL1 production by keratinocytes. (A) GAS killing kinetics with 32 μM of LL-37 and hepcidin; n = 3 per group. Representative of 2 independent experiments. (B) GAS growth curve in the presence of penicillin G, LL-37, hepcidin, or PBS; n = 3 per group. Representative of 2 independent experiments. (C) Bacterial recovering at 1 hour and 3 hours following incubation of log-phase GAS with murine primary keratinocytes (KC) from Hamp1lox/lox and Hamp1Δker mice. Data are representative of 2 independent experiments performed in triplicate. (D) Cytokines measured with the V-PLEX Proinflammatory Panel1 kit in the culture supernatant of murine primary keratinocytes stimulated for 1 or 3 hours with hepcidin or PBS; n = 3 per group. Representative of 3 independent experiments. (E) IL-8 ELISA on the culture supernatant of HaCat or a human 3D skin equivalent model stimulated with 3.6 μM hepcidin; n ≥ 3 per group. (F) CXCL1 levels measured by ELISA in the culture supernatant of murine primary keratinocytes stimulated for 3 hours with 3.6 μM hepcidin in the presence of PBS or 100 μM FPN inhibitor (2D-014); n ≥ 3 per group. Representative of 3 independent experiments. (G) CXCL1 levels measured by ELISA on the culture supernatant of murine primary keratinocytes stimulated for 3 hours with 500 μM ferric ammonium citrate (FAC); n = 3 per group. Representative of 3 independent experiments. Statistical analysis was performed using a 2-way ANOVA followed by Tukey’s test (A, B, and D), unpaired Student’s t test (E and G), or a 1-way ANOVA followed by Tukey’s test (C and F). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Figure 2 Hepcidin promotes CXCL1 production by keratinocytes. (A) GAS killing kinetics with 32 μM of LL-37 and hepcidin; n = 3 per group. Representative of 2 independent experiments. (B) GAS growth curve in the presence of penicillin G, LL-37, hepcidin, or PBS; n = 3 per group. Representative of 2 independent experiments. (C) Bacterial recovering at 1 hour and 3 hours following incubation of log-phase GAS with murine primary keratinocytes (KC) from Hamp1lox/lox and Hamp1Δker mice. Data are representative of 2 independent experiments performed in triplicate. (D) Cytokines measured with the V-PLEX Proinflammatory Panel1 kit in the culture supernatant of murine primary keratinocytes stimulated for 1 or 3 hours with hepcidin or PBS; n = 3 per group. Representative of 3 independent experiments. (E) IL-8 ELISA on the culture supernatant of HaCat or a human 3D skin equivalent model stimulated with 3.6 μM hepcidin; n ≥ 3 per group. (F) CXCL1 levels measured by ELISA in the culture supernatant of murine primary keratinocytes stimulated for 3 hours with 3.6 μM hepcidin in the presence of PBS or 100 μM FPN inhibitor (2D-014); n ≥ 3 per group. Representative of 3 independent experiments. (G) CXCL1 levels measured by ELISA on the culture supernatant of murine primary keratinocytes stimulated for 3 hours with 500 μM ferric ammonium citrate (FAC); n = 3 per group. Representative of 3 independent experiments. Statistical analysis was performed using a 2-way ANOVA followed by Tukey’s test (A, B, and D), unpaired Student’s t test (E and G), or a 1-way ANOVA followed by Tukey’s test (C and F). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.CC BY · PubMed Central
Figure 3 Hepcidin is required for CXCL1 production and neutrophil recruitment. (A) Anti-CXCL1 or (C) anti–polymorphonuclear leucocyte (PMN) immunostainings on skin of Hamp1lox/lox and Hamp1Δker mice challenged with GAS. PerkinElmer’s Lamina multilabel slide scanner Panoramic Viewer software. (B) CXCL1 ELISA on lysates from GAS-infected skin biopsies of Hamp1lox/lox (n = 5) and Hamp1Δker mice (n = 6). (D) Neutrophil count from GAS-infected skin biopsies of Hamp1lox/lox (n = 5) and Hamp1Δker mice (n = 4). (E) Area of necrotic ulcers in skin of Hamp1lox/lox and Hamp1Δker mice during GAS infection; n = 7 per group. (F) Scheme of the study protocol. (G) Bacterial count in the skin of Hamp1lox/lox and Hamp1Δker mice injected daily with CXCL1 or PBS; n ≥ 4 per group. Statistical analysis was performed using a Student’s t test (B and D), a 2-way ANOVA followed by Tukey’s test (E), or a 1-way ANOVA followed by Tukey’s test (G). *P < 0.05; **P < 0.01.
Figure 3 Hepcidin is required for CXCL1 production and neutrophil recruitment. (A) Anti-CXCL1 or (C) anti–polymorphonuclear leucocyte (PMN) immunostainings on skin of Hamp1lox/lox and Hamp1Δker mice challenged with GAS. PerkinElmer’s Lamina multilabel slide scanner Panoramic Viewer software. (B) CXCL1 ELISA on lysates from GAS-infected skin biopsies of Hamp1lox/lox (n = 5) and Hamp1Δker mice (n = 6). (D) Neutrophil count from GAS-infected skin biopsies of Hamp1lox/lox (n = 5) and Hamp1Δker mice (n = 4). (E) Area of necrotic ulcers in skin of Hamp1lox/lox and Hamp1Δker mice during GAS infection; n = 7 per group. (F) Scheme of the study protocol. (G) Bacterial count in the skin of Hamp1lox/lox and Hamp1Δker mice injected daily with CXCL1 or PBS; n ≥ 4 per group. Statistical analysis was performed using a Student’s t test (B and D), a 2-way ANOVA followed by Tukey’s test (E), or a 1-way ANOVA followed by Tukey’s test (G). *P < 0.05; **P < 0.01.CC BY · PubMed Central
Figure 4 Hepcidin is resistant to SpyCEP cleavage and has a therapeutic role in NF. (A) Mass spectroscopy analysis of CXCL1 or hepcidin incubated overnight with SpyCEP or PBS. Electrospray ionization generated a series of multiply charged ions (indicated as m/z; mass-to-charge ratio) from which the average molecular mass (m) of each was deduced. The blue arrows indicate uncleaved peptide peaks at 7.8 kDa (CXCL1) and 2.7 kDa (hepcidin). Red arrows show the cleavage products of CXCL1 with a small (1.3 kDa) and a big (5.9 kDa) fragment. (B) Therapeutic protocol. (C) Neutrophil count (3 measurements per individual mouse were averaged); n = 6 per group. (D) Weight variation and (E) bacterial count in spleen of WT infected mice treated with PBS or hepcidin (n = 9, red square) or PBS (n = 9, black square) during 4 days. Statistical analysis was performed using a Student’s t test (C), a 2-way ANOVA followed by Tukey’s test (D), or a Mann Whitney test (E). *P < 0.05.
Figure 4 Hepcidin is resistant to SpyCEP cleavage and has a therapeutic role in NF. (A) Mass spectroscopy analysis of CXCL1 or hepcidin incubated overnight with SpyCEP or PBS. Electrospray ionization generated a series of multiply charged ions (indicated as m/z; mass-to-charge ratio) from which the average molecular mass (m) of each was deduced. The blue arrows indicate uncleaved peptide peaks at 7.8 kDa (CXCL1) and 2.7 kDa (hepcidin). Red arrows show the cleavage products of CXCL1 with a small (1.3 kDa) and a big (5.9 kDa) fragment. (B) Therapeutic protocol. (C) Neutrophil count (3 measurements per individual mouse were averaged); n = 6 per group. (D) Weight variation and (E) bacterial count in spleen of WT infected mice treated with PBS or hepcidin (n = 9, red square) or PBS (n = 9, black square) during 4 days. Statistical analysis was performed using a Student’s t test (C), a 2-way ANOVA followed by Tukey’s test (D), or a Mann Whitney test (E). *P < 0.05.CC BY · PubMed Central

Verification

Claims the paper makes

6 Valid · 0 Not valid · 7 Not checked · 27 Own results and interpretations

17 more claims

Create a free account to see all 40 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 9
  • It may state two separate claims as one. 9

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 22 references

Cited by

See all 55

Metadata

Authors
Malerba, M., Louis, S., Cuvellier, S., Shambat, S. M., Hua, C., Gomart, C., Fouet, A., Ortonne, N., Decousser, J.-W., Zinkernagel, A. S., Mathieu, J. R. R., & Peyssonnaux, C.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • University of Zurich (CH)
  • Université Paris-Est Créteil (FR)
  • Assistance Publique – Hôpitaux de Paris (FR)
Corresponding author
Peyssonnaux, Carole
Venue
Journal of Clinical Investigation
Published
2019-12-03
Volume
130
Issue
1
Pages
329-334
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2979637231
Cited by
55
References
22
Citations by year
2026: 7 · 2025: 12 · 2024: 6 · 2023: 5 · 2022: 8 · 2021: 5 · 2020: 11
FWCI
4.41
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
  • HAL (submittedVersion)
  • HAL (submittedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • the European Research Council under the European Community’s Seventh Framework Program, the “Fondation pour la Recherche Médicale”, the Laboratory of Excellence GR-Ex. (FP7/2011-2015 Grant agreement no 261296,DEQ20160334903,ANR-11-LABX-0051)
  • Swiss National Science Foundation grant (grant 31003A_176252)
Topics
  • Life Sciences › Immunology and Microbiology › Microbiology › Antimicrobial Peptides and Activities
  • Health Sciences › Medicine › Infectious Diseases › Streptococcal Infections and Treatments
  • Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
Keywords
hepcidin, necrotizing fasciitis, Streptococcus pyogenes, neutrophil recruitment, CXCL1, keratinocytes, antimicrobial peptides, iron regulation, skin infections
MeSH terms
Animals, Disease Models, Animal, Epidermis, Humans, Neutrophils, Streptococcal Infections, Streptococcus pyogenes, Keratinocytes, Mice, Knockout, Fasciitis, Necrotizing, Mice, Chemokine CXCL1, Hepcidins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epidermal hepcidin is required for neutrophil response to bacterial infection. https://app.cochat.ai/papers/10.1172/jci126645
The paper
Malerba, M., Louis, S., Cuvellier, S., Shambat, S. M., Hua, C., Gomart, C., Fouet, A., Ortonne, N., Decousser, J.-W., Zinkernagel, A. S., Mathieu, J. R. R., & Peyssonnaux, C. (2019). Epidermal hepcidin is required for neutrophil response to bacterial infection. Journal of Clinical Investigation. https://doi.org/10.1172/jci126645

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.